Who
Lance Willsey
Director
Company insider
Files Form 4 as: Director, Edap Tms; Director, Exelixis; Director, Exact Sciences.
In numbers
- Trades disclosed
- 118
- Buys
- 13
- Sells
- 12
- Bought
- $2.2M
- Sold
- $10.2M
- Companies
- 3
- Companies where not an officer
- 3
- First trade
- 2 May 2006
- Last trade
- 14 Aug 2026
- Last filed
- 17 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 14 Aug 2026filed 17 Aug 2026 | FOCL Edap TmsMedical Devices | SEC FORM 4 Bought | $238K50,000 at $4.75 | filing |
| 14 Aug 2026filed 17 Aug 2026 | FOCL Edap TmsMedical Devices | SEC FORM 4 Bought | $238K50,000 at $4.75 | filing |
| 12 May 2026filed 13 May 2026 | Edap Tms Saoption or derivative · Medical Devices | SEC FORM 4 Code A | —114,285 at $0.00 | filing |
| 12 May 2026filed 13 May 2026 | FOCL Edap Tmsoption or derivative · Medical Devices | SEC FORM 4 Code A | —114,285 at $0.00 | filing |
| 26 May 2022filed 27 May 2022 | EXEL Exelixisoption or derivative · Biotechnology | SEC FORM 4 Code A | —42,422 at $0.00 | filing |
| 12 May 2022filed 13 May 2022 | EXEL Exelixisoption or derivative · Biotechnology | SEC FORM 4 Code M | —40,000 at $0.00 | filing |
| 12 May 2022filed 13 May 2022 | EXEL ExelixisBiotechnology | SEC FORM 4 Code M | $125K40,000 at $3.13 | filing |
| 12 May 2022filed 13 May 2022 | EXEL ExelixisBiotechnology | SEC FORM 4 Sold | $786K40,000 at $19.65 | filing |
| 27 May 2021filed 28 May 2021 | EXEL Exelixisoption or derivative · Biotechnology | SEC FORM 4 Code A | —33,549 at $0.00 | filing |
| 23 Feb 2021filed 24 Feb 2021 | EXEL Exelixisoption or derivative · Biotechnology | SEC FORM 4 Code M | —40,000 at $0.00 | filing |
| 23 Feb 2021filed 24 Feb 2021 | EXEL ExelixisBiotechnology | SEC FORM 4 Code M | $135K40,000 at $3.38 | filing |
| 23 Feb 2021filed 24 Feb 2021 | EXEL ExelixisBiotechnology | SEC FORM 4 Sold | $859K39,200 at $21.92 | filing |
| 23 Feb 2021filed 24 Feb 2021 | EXEL ExelixisBiotechnology | SEC FORM 4 Sold | $18K800 at $22.34 | filing |
| 16 Feb 2021filed 24 Feb 2021 | EXEL ExelixisBiotechnology | SEC FORM 4 Sold | $1.1M50,000 at $21.90 | filing |
| 4 Dec 2020filed 4 Dec 2020 | EXEL Exelixisoption or derivative · Biotechnology | SEC FORM 4 Code M | —106,142 at $0.00 | filing |
| 4 Dec 2020filed 4 Dec 2020 | EXEL ExelixisBiotechnology | SEC FORM 4 Code M | $618K106,142 at $5.82 | filing |
| 21 May 2020filed 22 May 2020 | EXEL Exelixisoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,750 at $0.00 | filing |
| 18 May 2020filed 20 May 2020 | EXEL Exelixisoption or derivative · Biotechnology | SEC FORM 4 Code M | —30,000 at $0.00 | filing |
| 18 May 2020filed 20 May 2020 | EXEL ExelixisBiotechnology | SEC FORM 4 Code M | $137K30,000 at $4.58 | filing |
| 18 May 2020filed 20 May 2020 | EXEL ExelixisBiotechnology | SEC FORM 4 Sold | $788K30,000 at $26.26 | filing |
News
No headline names them, or the companies they trade most, lately.